Gene Therapy of Cardiac Hypertrophy


Funded period

2022 – 2024

Granted budget

€ 894,000

Indication

Heart failure

Therapeutic Principle

Gene therapy

Principal Investigator

Oliver Müller

The project wants to test a novel therapeutic approach in a pig model of acquired cardiac hypertrophy using inhibition of the transcription factor NFAT, which has been shown to control the hypertrophic gene programme in aortic stenosis but also hereditary forms of cardiac hypertrophy.

Cardiac hypertrophy can be caused by obstruction of the aortic valve or by hereditary diseases of the heart muscle. With disease progression, cardiac hypertrophy results frequently in heart failure that may persist even after treatment of underlying causes. In both hereditary forms and acquired forms of cardiac hypertrophy, treatment options are limited. Therefore, we want to test a novel therapeutic approach in a pig model of acquired cardiac hypertrophy using inhibition of the transcription factor NFAT, that has been shown to control the hypertrophic gene programme in aortic stenosis but also hereditary forms of cardiac hypertrophy.